Results 161 to 170 of about 121,615 (309)

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial

open access: yesThe Oncologist, EarlyView., 2021
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth   +10 more
wiley   +1 more source

Thyroid Hormone Receptors

open access: yesFolia Endocrinologica Japonica, 1977
openaire   +2 more sources

N6‐Methyladenosine (m6A) in Liver Disease: Pathogenic Mechanisms and Therapeutic Potential

open access: yesiNew Medicine, EarlyView.
ABSTRACT Accumulating evidence highlights the critical role of epigenetic modifications, particularly N6‐methyladenosine (m6A), in liver disease. As the most abundant RNA modification in eukaryotic cells, m6A is dynamically regulated by multicomponent m6A methyltransferases (e.g., METTL3 and METTL14), demethylases (FTO and ALKBH5), and m6A‐binding ...
Yingfen Chen   +6 more
wiley   +1 more source

Deep learning‐based prediction of cervical lymph node metastasis and genetic alterations from whole‐slide images of thyroid cancer frozen sections

open access: yesInterdisciplinary Medicine, EarlyView.
Deep learning models accurately predict cervical lymph node metastasis and key genetic mutations (BRAF/TERT) directly from thyroid cancer frozen sections. This AI‐driven pipeline provides a rapid real‐time tool to guide intraoperative surgical decisions, helping to optimize surgical extent and prevent both over‐ and under‐treatment without the need for
Mingxing Qiu   +20 more
wiley   +1 more source

SUMOylation regulates tumorigenesis and progression: Molecular mechanisms and therapeutic applications

open access: yesInterdisciplinary Medicine, EarlyView.
SUMOylation, a dynamic post‐translational modification, acts as a master regulator at the heart of tumor malignancy. Our work delineates how the SUMOylation cycle—mediated by E1/E2/E3 enzymes and reversed by SENPs—orchestrates multiple hallmarks of cancer. The central pathway converges on three critical pathological axes: 1.
Yimao Wu   +6 more
wiley   +1 more source

Thyroid hormones, mitochondria, aging, and cancer. [PDF]

open access: yesFront Endocrinol (Lausanne)
Glinsky G, Hercbergs A, Davis PJ.
europepmc   +1 more source

Home - About - Disclaimer - Privacy